Chronic Pancreatitis Clinical Trial
Official title:
A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy
Verified date | September 2018 |
Source | AzurRx SAS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase IIa study sponsored by AzurRx SAS and Syneos Health is a local representative
sponsor and involves testing of a new medication for the compensation of exocrine pancreatic
insufficiency (EPI) caused by chronic pacreatitis (CP) and/or distal pancreatectomy. The new
medication is called MS1819 Spray Dried (MS1819-SD) which is a lipase produced by the LIP2
gene of Yarrowia lipolytica using recombinant DNA technology.
The primary purpose of this study is to investigate the safety of escalating doses of study
drug MS1819-SD in people with chronic pancreatitis. This enzyme has demonstrated an
appropriate profile to compensate the pancreatic lipase (enzyme) deficiency that is common
with CP patients. The deficiency in this enzyme can be responsible of greasy diarrhea, fecal
urge and weight loss.
The design of the study is open-label, meaning that all eligible participants will receive
the study drug MS1819-SD. The MS1819-SD dose will increase throughout the study during dose
escalation visits in each treatment period; study includes a total of four treatment periods.
The total duration of the MS1819-SD treatment phase is of 48-60 days, The total duration of
patient participation in the study is of 74-93 days.
Approximately twelve patients will be enrolled in this study.
Status | Completed |
Enrollment | 11 |
Est. completion date | June 29, 2018 |
Est. primary completion date | June 29, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Signed and dated informed consent form, 2. Age >18 years, 3. Male or female, 4. Body weight within the range [50-100 Kg] for males or [40-90 Kg] for females, 5. Distal pancreatectomy for any disorder (e.g. acute pancreatitis or its complications, CP or its complications, pancreatic endocrine or exocrine cancer, or others) and/or CP of any etiology (e.g. alcohol, genetics, hypercalcemia, or others) of grade 2 or higher (Cambridge classification), 6. Faecal pancreatic elastase-1 <100 µg/g of stools at screening or within one month of the screening visit, 7. CFA measurement = 75% at washout 8. Female patients must be post-menopausal (defined as at least 12 months post cessation of menses), surgically sterile or, if of childbearing potential, using a reliable method of contraception during the study. 9. Being considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator. Exclusion Criteria: 1. Cystic fibrosis, 2. Total or partial gastrectomy, 3. Cephalic or total duodenopancreatectomy, 4. Documented fibrosing colonopathy, 5. Any small bowel disease possibly responsible for malabsorption, including small intestinal bacterial overgrowth, celiac disease, small bowel resection =1 meter length, etc., 6. Acute pancreatitis or exacerbation of CP =3 months, 7. Pancreatectomy for exocrine or endocrine cancer =1 year, 8. Metastatic or locally recurrent exocrine pancreatic cancer, 9. Known hypersensitivity or other severe reaction to any ingredient of the investigational medicinal product, 10. Bilirubin >3 times ULN (upper limit normal), |
Country | Name | City | State |
---|---|---|---|
Australia | CMAX | Adelaide | South Australia |
Australia | Mackay Institute of Research and Innovation | Mackay | Queensland |
Australia | Linear Research | Perth | Western Australia |
France | Ho^pital Timone Adulte (CIC-CPCET) | Marseille | |
New Zealand | Christchurch Clinical Studies Trust | Christchurch | |
New Zealand | P3 Research | Wellington |
Lead Sponsor | Collaborator |
---|---|
AzurRx SAS |
Australia, France, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Investigate safety of escalating doses of MS1819-SD as measured by number of participants with adverse events including clinical or laboratory abnormalities | Safety variables will be monitored by physical examination with particular attention paid to immunoallergic events and digestive symptomatology. In addition, laboratory tests will include haematology and biochemistry. | 60 days | |
Secondary | Investigate the efficacy of MS1819-SD in patients by the Coefficient of Fat Absorption change from baseline | The primary efficacy endpoint is the Coefficient Fat Absorption (CFA) change from baseline.The secondary efficacy endpoints are the number of daily evacuations per day, the consistency of stools assessed by the Bristol scale (from Type 1 to Type 7) and the weight of stools during the stool collection period. | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03112759 -
Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis
|
N/A | |
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Active, not recruiting |
NCT02965898 -
The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis
|
N/A | |
Completed |
NCT02868047 -
Establishing Standards for Normal Pancreatic EUS
|
N/A | |
Completed |
NCT01452217 -
Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00685087 -
A Prospective Study of Natural History of Pancreatitis
|
N/A | |
Completed |
NCT04949828 -
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
|
||
Recruiting |
NCT06068426 -
Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management
|
N/A | |
Active, not recruiting |
NCT05764629 -
An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
|
||
Active, not recruiting |
NCT05042284 -
Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis
|
N/A | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Recruiting |
NCT06015945 -
Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis
|
N/A | |
Completed |
NCT04619511 -
Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
|
||
Completed |
NCT03283566 -
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
|
Phase 2 | |
Recruiting |
NCT03434392 -
QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing
|
N/A | |
Completed |
NCT01318369 -
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain
|
Phase 2 | |
Completed |
NCT01430234 -
Enzyme Suppletion in Exocrine Pancreatic Dysfunction
|
Phase 4 | |
Terminated |
NCT01442454 -
Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis
|
N/A | |
Completed |
NCT00755573 -
Pain and Chronic Pancreatitis - Clinical End Experimental Studies
|
Phase 2/Phase 3 |